Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

AstraZeneca submits sNDAs for Seroquel XR tablets

Jan. 3, 2008

Modulation of LR11 protein levels by dietary DHA may be beneficial for AD prevention

Jan. 3, 2008

Cognition-enhancing activity of novel inverse agonist of GABA-A alpha 5 subunit receptors

Jan. 3, 2008

Studies support serotonin inverse agonist combination therapy for schizophrenia

Jan. 3, 2008

Forest and Cypress submit NDA to FDA for milnacipran for fibromyalgia syndrome

Jan. 2, 2008

Phase I ADL-5747 trial for treatment of pain to be initiated shortly under IND

Jan. 2, 2008

Wide therapeutic potential seen for sanofi-aventis' GlyT-1 inhibitor SSR-103800

Jan. 2, 2008

Preclinical studies suggest K+ channel TASK-1 to be potential target of antiepileptic drugs

Jan. 2, 2008

Phase IIa MEM-3454 trial begins for cognitive impairment in schizophrenia

Jan. 2, 2008

U.K. report cites Hemispherx's Ampligen as a potential aid for CFS

Jan. 2, 2008

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...